Tyrosine kinase inhibitors (TKIs), which are the standard treatment for CML, improve survival rates despite potential side effects and risks of residual disease if treatment is discontinued, referring to the persistence of BCR-ABL1 transcripts, which can lead to a loss of molecular response and potential relapse, if treatment is discontinued [1]. The gene discussed is ABL1; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.